Christopher Rovaldi, Chief Operating Officer at Keros Therapeutics, Inc. (KROS), sold 1,728 shares at $65.00 ($112K) on 2022-04-06, disclosed to the SEC on 2022-04-08.
Open-market sale of $112k KROS by Chief Operating Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| XLRN | SELL | 2018-01-17 | $495K | — | Filing → |
| XLRN | SELL | 2018-01-04 | $157K | — | Filing → |
| XLRN | SELL | 2017-09-14 | $538K | — | Filing → |